Table 1.

Testing methods used to determine HPV prevalence in the Compass pilot study samples.^a

Monitoring Strategy	Technology	Samples included in HPV prevalence estimation	Comments
LA	LA	All LA oncogenic positive samples
cobas	cobas	All cobas positive samples
cobas/LA	cobas	All cobas positive samples counted as HPV positive	Only samples testing non-16/18 HPV positive with cobas are re-tested by LA. If LA returns a HPV16 or/and 18 result then the cobas non-16/18 HPV positive sample contributes to HPV16 or 16/18 prevalence.
		AND	Samples testing cobas non-16/18 HPV positive and LA negative contribute towards non-16/18 HPV prevalence
	LA	Samples with cobas result of non-16/18 HPV positive are counted as HPV16/18 if LA returns a HPV16/18 result

^aAdditional combined testing strategies were also explored (Algorithm A and B) as presented in appendix Table S1.